nach oben

Sleep and Breathing

Erschienen in:

31.01.2023 | Sleep Breathing Physiology and Disorders • Original Article

Sacubitril/valsartan mitigated intermittent hypoxia related intestinal microbiota alteration and aortic injury

verfasst von: Jinfeng Wang, Hongxiang Zhang, LiJuan Wu, Dasheng Lu

Erschienen in: Sleep and Breathing | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the influence of sacubitril valsartan sodium (SVS) on chronic intermittent hypoxia (IH) related gut microbiome composition alteration and aortic injury.

Methods

Experiments were performed using SD rats, which were divided into three groups: control, IH, and SVS group. O₂ concentration was decreased to 7–8% at nadir approximately every 3 min in IH group (8 h per day for 6 weeks) or was left unchanged in control group. Rats in SVS group were orally gavaged with SVS at the dosage of 30 mg/kg/day (2 weeks after chronic IH exposure). At week 6, fecal and aortic samples were harvested for 16 s rDNA analysis and histological analysis, respectively.

Results

Principal coordinate analysis and non-metric multidimensional scaling analysis indicated that the bacterial community was altered by chronic IH exposure, while SVS treatment restored the intestinal microbial communities. Further analysis showed that IH decreased the relative abundance of Lactobacillus and Prevotella, while rats treated with SVS was enriched with Firmicutes, Bacilli, Prevotellaceae, and Lactobacillus, which was similar to control rats. Immunohistochemical staining showed that SVS prevented the upregulation of transforming growth factor-β1 and tumor necrosis factor-alpha in the aorta.

Conclusion

SVS prevented aortic adverse response to IH, possibly through modulating intestinal microbiota.

Nur mit Berechtigung zugänglich

Benjafield A et al (2018) in B67. Risk and prevalence of sleep disordered breathing A3962-A3962 (American Thoracic Society)

Devulapally K, Pongonis R Jr, Khayat R (2009) OSA: the new cardiovascular disease: part II: overview of cardiovascular diseases associated with obstructive sleep apnea. Heart Fail Rev 14:155–164. https://doi.org/10.1007/s10741-008-9101-2CrossRefPubMed

Drager LF et al (2005) Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 172:613–618. https://doi.org/10.1164/rccm.200503-340OCCrossRefPubMed

Drager LF, Polotsky VY, Lorenzi-Filho G (2011) Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 140:534–542. https://doi.org/10.1378/chest.10-2223CrossRefPubMedPubMedCentral

Ma L, Zhang J, Liu Y (2016) Roles and mechanisms of obstructive sleep apnea-hypopnea syndrome and chronic intermittent hypoxia in atherosclerosis: evidence and prospective. Oxid Med Cell Longev 2016:8215082. https://doi.org/10.1155/2016/8215082CrossRefPubMedPubMedCentral

Tang WH, Kitai T, Hazen SL (2017) Gut microbiota in cardiovascular health and disease. Circ Res 120:1183–1196. https://doi.org/10.1161/circresaha.117.309715CrossRefPubMedPubMedCentral

Farré N, Farré R, Gozal D (2018) Sleep apnea morbidity: a consequence of microbial-immune cross-talk? Chest 154:754–759. https://doi.org/10.1016/j.chest.2018.03.001CrossRefPubMed

Zhang H et al (2019) Neprilysin inhibitor-angiotensin II receptor blocker combination therapy (sacubitril/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E-deficient mice. Sci Rep 9:6509. https://doi.org/10.1038/s41598-019-42994-1CrossRefPubMedPubMedCentral

Lu D, Wang J, Zhang H, Shan Q, Zhou B (2020) Renal denervation improves chronic intermittent hypoxia induced hypertension and cardiac fibrosis and balances gut microbiota. Life Sci 262:118500CrossRefPubMed

10.

Wang Y et al (2014) Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function. Oxidative Med Cell longev 2014:123963. https://doi.org/10.1155/2014/123963CrossRef

11.

Zhang F et al (2020) 5-Fluorouracil induced dysregulation of the microbiome-gut-brain axis manifesting as depressive like behaviors in rats. Biochim Biophys Acta Mol Basis Dis 1866:165884. https://doi.org/10.1016/j.bbadis.2020.165884CrossRefPubMed

12.

Langille MG et al (2013) Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 31:814–821. https://doi.org/10.1038/nbt.2676CrossRefPubMedPubMedCentral

13.

Maslowski KM et al (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282–1286. https://doi.org/10.1038/nature08530CrossRefPubMedPubMedCentral

14.

Lucking EF et al (2018) Chronic intermittent hypoxia disrupts cardiorespiratory homeostasis and gut microbiota composition in adult male guinea-pigs. EBioMedicine 38:191–205. https://doi.org/10.1016/j.ebiom.2018.11.010CrossRefPubMedPubMedCentral

15.

Allahdadi KJ, Walker BR, Kanagy NL (2005) Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension (Dallas, Tex. : 1979) 45:705–709. https://doi.org/10.1161/01.hyp.0000153794.52852.04CrossRefPubMed

16.

Gabryelska A, Łukasik ZM, Makowska JS, Białasiewicz P (2018) Obstructive sleep apnea: from intermittent hypoxia to cardiovascular complications via blood platelets. Front Neurol 9:635. https://doi.org/10.3389/fneur.2018.00635CrossRefPubMedPubMedCentral

17.

Sauer AJ et al (2019) Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev 24:167–176. https://doi.org/10.1007/s10741-018-9757-1CrossRefPubMed

18.

Yandrapalli S, Khan MH, Rochlani Y, Aronow WS (2018) Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis 12:217–231. https://doi.org/10.1177/1753944718784536CrossRefPubMedPubMedCentral

19.

Moreno-Indias I et al (2015) Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J 45:1055–1065. https://doi.org/10.1183/09031936.00184314CrossRefPubMed

20.

Tripathi A et al (2019) Intermittent hypoxia and hypercapnia reproducibly change the gut microbiome and metabolome across rodent model systems. mSystems 4. https://doi.org/10.1128/mSystems.00058-19

21.

Durgan DJ et al (2016) Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67:469–474. https://doi.org/10.1161/hypertensionaha.115.06672CrossRefPubMed

22.

Tripathi A et al (2018) Intermittent hypoxia and hypercapnia, a hallmark of obstructive sleep apnea, alters the gut microbiome and metabolome. mSystems 3. https://doi.org/10.1128/mSystems.00020-18

23.

Yang T et al (2015) Gut dysbiosis is linked to hypertension. Hypertension (Dallas, Tex. : 1979) 65:1331–1340. https://doi.org/10.1161/hypertensionaha.115.05315CrossRefPubMed

24.

Sanada TJ et al (2020) Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model. Pulm Circ 10:2045894020929147. https://doi.org/10.1177/2045894020929147CrossRefPubMedPubMedCentral

25.

Li J et al (2017) Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 5:14. https://doi.org/10.1186/s40168-016-0222-xCrossRefPubMedPubMedCentral

26.

Zuo K et al (2019) Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. GigaScience 8. https://doi.org/10.1093/gigascience/giz058

27.

Jonsson AL, Bäckhed F (2017) Role of gut microbiota in atherosclerosis. Nat Rev Cardiol 14:79–87. https://doi.org/10.1038/nrcardio.2016.183CrossRefPubMed

28.

Ryan S, Taylor CT, McNicholas WT (2005) Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:2660–2667. https://doi.org/10.1161/circulationaha.105.556746CrossRefPubMed

29.

Murphy AM, Thomas A, Crinion SJ, Kent BD, Tambuwala MM (2017) Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Eur Respir J 49. https://doi.org/10.1183/13993003.01731-2016

30.

Hakansson A, Molin G (2011) Gut microbiota and inflammation. Nutrients 3:637–682. https://doi.org/10.3390/nu3060637CrossRefPubMedPubMedCentral

31.

Cui L, Zhao T, Hu H, Zhang W, Hua X (2017) Association study of gut flora in coronary heart disease through high-throughput sequencing. Biomed Res Int 2017:3796359. https://doi.org/10.1155/2017/3796359

32.

Mayerhofer CC et al (2020) Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail 7:456–466CrossRefPubMedPubMedCentral

33.

Liao P-H et al (2016) Lactobacillus reuteri GMNL-263 reduces hyperlipidaemia and the heart failure process in high-calorie diet-fed induced heart dysfunction in rats. J Funct Foods 20:226–235CrossRef

34.

Zhao L, Xing C, Sun W, Hou G, Yang G (2018) Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition. Cancer Chemother Pharmacol 82:999–1008. https://doi.org/10.1007/s00280-018-3691-8CrossRefPubMed

35.

Toral M et al (2014) The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clin Sci (London England : 1979) 127:33–45. https://doi.org/10.1042/cs20130339CrossRef

36.

Malik M et al (2018) Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease. Circ Res 123:1091–1102. https://doi.org/10.1161/circresaha.118.313565CrossRefPubMedPubMedCentral

37.

Chaumais MC et al (2020) Additive protective effects of sacubitril/valsartan and bosentan on vascular remodeling in experimental pulmonary hypertension. Cardiovasc Res. https://doi.org/10.1093/cvr/cvaa200CrossRef

Titel: Sacubitril/valsartan mitigated intermittent hypoxia related intestinal microbiota alteration and aortic injury
verfasst von: Jinfeng Wang
Hongxiang Zhang
LiJuan Wu
Dasheng Lu
Publikationsdatum: 31.01.2023
Verlag: Springer International Publishing
Erschienen in: Sleep and Breathing / Ausgabe 5/2023
Print ISSN: 1520-9512
Elektronische ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-023-02781-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Sacubitril/valsartan mitigated intermittent hypoxia related intestinal microbiota alteration and aortic injury

Abstract

Objective

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Adherence to continuous positive airway pressure treatment in a cohort of elderly adults with newly diagnosed obstructive sleep apnea

Subclinical and latent cardiac dysfunction in obstructive sleep apnea and effectiveness of continuous positive airway pressure

Insomnia in Chinese patients with chronic schizophrenia: prevalence, clinical correlates and relationship with cognitive impairment

A review on the treatment of Cheyne Stokes Breathing in patients with congestive heart failure

Renal denervation alleviates chronic obstructive sleep apnea-induced atrial fibrillation via inhibition of atrial fibrosis and sympathetic hyperactivity

Correlation between nocturnal intermittent hypoxemia and mild cognitive impairment in the older adult and the role of BDNF Val66Met polymorphism: a hospital-based cross-sectional study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin